Clinical studies have been conducted using the Re5 pulses for treatment of Resistant Major Depression. In 2010 a double blinded, placebo-controlled study by Martiny et al. (2010) showed significant improvements in patients suffering from Resistant Major Depression after 5 weeks of treatment. Bech et al.(2011) analyzed data from that study and concluded ” Active T-PEMF was found superior to sham T-PEMF within the pharmacopsychometric triangle with a clinically significant effect size. A dose remission study was published in 2014 (Straasø et al., 2014) showing a remission rate of 73% after 8 weeks of home treatment with the Re5 medical device. A follow up study was published (Bech et al., 2015) revealing that amongst the 73% that obtained remission in the study by Straasø et al. (2015), 2 years later 52 % were still in remission. Re5 gained its CE approval in September 2015.
New 2020 T-PEMF publication based on a multicenter 8-week single-arm cohort study concerning Transcranial pulsed electromagnetic fields for treatment-resistant depression using Re5 Neuro Treatment System.
Link to publication
Martiny K., Lunde M., Bech P.
Transcranial low voltage pulsed electromagnetic fields in patients with treatment-resistant depression.
Biol. Psychiatry. 2010 Jul 15;68(2):163-9
Bech P, Gefke M, Lunde M, Lauritzen L, Martiny K. The Pharmacopsychometric
Triangle to Illustrate the Effectiveness of T-PEMF Concomitant with Antidepressants in Treatment Resistant Patients:
A Double-Blind, Randomised, Sham-Controlled Trial Revisited with Focus on the Patient-Reported Outcomes.
Depress Res Treat. 2011;2011:806298.
Straasø, B, Lauritzen, L, Lunde, M, Vinberg, M, Lindberg, L, Roj Larsen, E, Dissing, S, Bech, P.
Dose-remission of pulsating electromagnetic fields as augmentation in therapy-resistant depression:
a randomized, double blind controlled study.
Acta Neuropsychiatrica 2014.
Bech, P, Lindberg, L, Straasø, B, Roj Larsen, E.
2-year follow-up study of patients participating in our transcranial pulsating electromagnetic fields
(T-PEMF) augmentation in treatment-resistant depression.
Acta Neuropsychiatrica 2015.